Genetic Basis And Clinical Perspectives Of Breast Cancer
DOI:
https://doi.org/10.53555/jaz.v44iS6.3708Keywords:
Breast cancer, BRCA mutations, Disease staging, Hereditary risk, Treatment strategiesAbstract
Breast cancer, a widespread malignancy affecting women, originates in the epithelial tissues of the breast. This study explores the significance of BRCA1 and BRCA2 genes in breast cancer etiology. Approximately 5% to 10% of breast cancer cases are hereditary, resulting from germline mutations in these genes. BRCA mutations increase the risk of breast cancer, with carriers facing a likelihood of 45% to 75% of developing the disease. Additionally, the aggressive phenotype of BRCA-related breast cancers is marked by features like triple-negative attributes and higher grades. In India, the incidence of breast cancer is escalating, projected to reach 250,000 cases by 2030. Alarming mortality rates underscore the necessity for effective interventions. The five-stage classification of breast cancer—from non-invasive disease in Stage 0 to metastatic spread in Stage IV—provides a framework for diagnosis and treatment. Earlystage breast cancers are manageable with surgery and hormone therapy. In locally advanced breast cancer (Stage III), a combination of
chemotherapy and surgery is employed after metastatic spread to lymph nodes and other sites. Stage IV breast cancer, representing the most advanced phase, presents significant treatment challenges. Current therapies encompass systemic drugs, radiation therapy, chemotherapy, and surgery, although achieving a definitive cure remains elusive. This study emphasizes the crucial role of BRCA mutations in breast cancer susceptibility, stressing the importance of genetic screening and targeted interventions. Furthermore, it explores the complexities of disease staging, guiding treatment strategies based on disease extent. Despite considerable progress, continuous research efforts are essential to enhancing diagnostic precision and developing more effective treatments for this intricate and multifaceted disease (Łukasiewicz et al., 2021; Smolarz et al., 2022).
Downloads
References
Apostolou, P., & Papasotiriou, I. (2017). Current perspectives on CHEK2 mutations in breast cancer. Breast
cancer (Dove Medical Press), 9, 331–335. https://doi.org/10.2147/BCTT.S111394
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021). Current State of Breast Cancer Diagnosis, Treatment,
and Theranostics. Pharmaceutics, 13(5), 723. https://doi.org/10.3390/pharmaceutics13050723
Criscitiello, C., & Corti, C. (2022). Breast Cancer Genetics: Diagnostics and Treatment. Genes, 13(9), 1593.
https://doi.org/10.3390/genes13091593
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu,
B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer
development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular
pathogenesis. Genes & diseases, 5(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
Fu, X., Tan, W., Song, Q., Pei, H., & Li, J. (2022). BRCA1 and Breast Cancer: Molecular Mechanisms and
Therapeutic Strategies. Frontiers in cell and developmental biology, 10, 813457.
https://doi.org/10.3389/fcell.2022.813457
Lee, A., Moon, B. I., & Kim, T. H. (2020). BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment
and Prevention Strategies. Annals of laboratory medicine, 40(2), 114–121.
https://doi.org/10.3343/alm.2020.40.2.114
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast CancerEpidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An
Updated Review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287
Moo, T. A., Sanford, R., Dang, C., & Morrow, M. (2018). Overview of Breast Cancer Therapy. PET
clinics, 13(3), 339–354. https://doi.org/10.1016/j.cpet.2018.02.006
Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015). Breast
Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast
cancer : basic and clinical research, 9(Suppl 2), 17–34. https://doi.org/10.4137/BCBCR.S29420
Ortega, M. A., Fraile-Martínez, O., Asúnsolo, Á., Buján, J., García-Honduvilla, N., & Coca, S. (2020).
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. Journal of
oncology, 2020, 9258396. https://doi.org/10.1155/2020/9258396
Paul, A., & Paul, S. (2014). The breast cancer susceptibility genes (BRCA) in breast and ovarian
cancers. Frontiers in bioscience (Landmark edition), 19(4), 605–618. https://doi.org/10.2741/4230
Journal of Advanced Zoology
Available online at: https://jazindia.com 2272
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020). TP53 Mutations and Outcomes in Breast Cancer:
Reading beyond the Headlines. Trends in cancer, 6(2), 98–110.
https://doi.org/10.1016/j.trecan.2020.01.007
Shiovitz, S., & Korde, L. A. (2015). Genetics of breast cancer: a topic in evolution. Annals of oncology :
official journal of the European Society for Medical Oncology, 26(7), 1291–1299.
https://doi.org/10.1093/annonc/mdv022
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022). Breast Cancer-Epidemiology, Classification,
Pathogenesis and Treatment (Review of Literature). Cancers, 14(10), 2569.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Bidisha Ghosh, Monoswita Chakraborty, Semanti Ghosh, Bidisha Ghosh, Subhasis Sarkar, Suranjana Sarkar

This work is licensed under a Creative Commons Attribution 4.0 International License.